Overview
- HHS submitted an “interim access policy” to the Office of Management and Budget on Oct. 15, 2026, which puts the proposal before the White House for review and could reassure compounding pharmacies they will not be targeted for making certain peptides.
- The plan is reported to aim at allowing pharmacies to temporarily compound popular peptides such as BPC-157 by using enforcement discretion rather than completing formal rulemaking.
- In July, an HHS-selected external advisory panel recommended dropping restrictions on six of seven peptides under review even though FDA staff scientists said none had enough clinical study to prove safety or effectiveness.
- Safety concerns cited by the FDA include risks of contamination, allergic reactions and possible tumor growth, and critics say the HHS-selected panel included industry-connected experts while patients who report harm were underrepresented.
- Major telehealth firms have said they will offer peptides if access is eased and analysts put the potential market at $2 billion to $3 billion, which could quickly expand commercial availability if the administration moves forward.